We also explored the mechanism of action of combination treatment with lenvatinib plus PD-1 blockade by using flow cytometry, immunohistochemistry, and transcriptome analyses of tumor tissues treated with lenvatinib, PD-1 blockade, or lenvatinib plus PD-1 blockade. Here, PDCD1 is linked to neoplasm.